Salute e Benessere
NF-κB Inhibitors Market to Witness Accelerated Expansion Across the 7MM through 2034 | DelveInsight
Discover which indication is expected to grab the major NF-κB inhibitors market share @
NF-κB sits at the crossroads of inflammation and tumor biology, so the pathway's involvement across autoimmune, neuroinflammatory and many cancers creates broad clinical demand for effective inhibitors.
Because NF-κB signaling is implicated in Alzheimer's, Parkinson's, long-COVID neurological symptoms and other CNS disorders, pipeline activity aimed at neurodegeneration (and the need for blood-brain-barrier-permeable molecules) is expanding market opportunity. BioVie's bezisterim (NE3107) programs illustrate that trend.
NF-κB inhibitors has a pipeline consisting of promising products such as , , and others.
Despite its central role in pathophysiology, there are currently no NF-κB inhibitors approved for clinical use, underscoring the unmet medical need and the complexity of targeting this pathway effectively and safely. Several emerging NF-κB inhibitors are now progressing through clinical trials, reflecting renewed interest and innovation in this space. , developed by , is the most advanced candidate, currently in a Phase III trial for Alzheimer's disease, and in Phase II studies for Parkinson's disease and long COVID. If successful, it could become the first-in-class NF-κB inhibitor in neurology.
In oncology, from is in Phase II trials for recurrent glioblastoma, and is also being explored for diffuse intrinsic pontine gliomas (DIPG). Similarly, from is advancing through trials in rectal, ovarian, and endometrial cancers, with a focus on enhancing the effect of chemoradiation by reducing oxidative stress and inflammation through NF-κB modulation.
In the inflammatory disease space, niclosamide, a repurposed anthelmintic with NF-κB inhibitory properties, is being developed by . FW-UP is in Phase II for ulcerative proctitis and proctosigmoiditis, while FW-ICI-AC is targeting immune checkpoint inhibitor (ICI)-associated colitis, a rising complication in immuno-oncology.
However, despite encouraging preclinical and early clinical data, the development of NF-κB inhibitors has historically been challenged by concerns over off-target effects and immunosuppression, given NF-κB's ubiquitous role in immune homeostasis. Future success will depend on the ability to achieve pathway specificity, optimize dosing, and identify disease contexts where modulation of NF-κB offers a clear benefit-risk advantage.
Learn more about the NF-κB inhibitors @
NF-κB inhibitors have a pipeline consisting of promising products such as , and others, which are in late- and mid-stage clinical development.
Biovie is investigating across Alzheimer's disease, Parkinson's disease, and Long COVID. Within these clinical programs, the company is also assessing whether the therapy can influence , specifically by evaluating its capacity to lower DNA methylation levels in trial participants.
Bezisterim is an that acts as an targeting extracellular signal-regulated kinase (ERK). Research indicates that it selectively blocks ERK- and NF-κB–driven inflammatory mediators, such as tumor necrosis factor alpha (TNF-α), while preserving their normal physiological roles.
is an oral, niclosamide-based small molecule anti-inflammatory therapy being developed for the treatment of ulcerative proctitis (UP) and ulcerative proctosigmoiditis (UPS). It is currently under evaluation in a Phase IIb clinical trial to assess the safety and potential effectiveness of niclosamide in patients with these conditions. FW-UP may offer a safe treatment option for UP and UPS, which are localized forms of ulcerative colitis, a chronic inflammatory bowel disease (IBD) characterized by superficial ulcerations in the inner mucosal lining of the large intestine that do not extend into the muscle wall.
is another oral niclosamide-based small molecule anti-inflammatory therapy from Entero Therapeutics, designed for the treatment of immune checkpoint inhibitor (ICI)-induced colitis and diarrhea in patients with metastatic cancer. The trial, a Phase IIa study evaluating the safety and potential efficacy of niclosamide for ICI-AC, received FDA IND clearance in Q4 2021.
The anticipated launch of these emerging therapies are poised to transform the NF-κB inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the NF-κB inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about NF-κB inhibitors clinical trials, visit @
NF-κB is a family of inducible transcription factors that play a key role in controlling immune and inflammatory responses. Often simply called NF-κB, these proteins usually function as dimers, with the canonical p50/p65 (NF-κB1/RelA) heterodimer being the most extensively studied. As a widely expressed and highly versatile transcription factor, NF-κB integrates signals from diverse stimuli, such as cytokines, pathogens, stress, and cellular damage. It acts as a crucial downstream effector in complex intracellular signaling pathways, regulating genes involved in inflammation, innate and adaptive immunity, cell proliferation, differentiation, survival, and apoptosis. NF-κB is particularly essential for coordinating immune responses to pathogens and maintaining immune system balance.
The NF-κB Inhibitors market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2020–2034 across the leading markets. The total diagnosed prevalent cases of Parkinson's disease in the 7MM were in 2024. On the other hand, the total diagnosed prevalent cases of Alzheimer's disease in the 7MM were in the same year.
The NF-κB Inhibitors target patient pool is segmented into:
Discover more about NF-κB inhibitors in development @
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key glioblastoma companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key glioma companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/nf-b-inhibitors-market-to-witness-accelerated-expansion-across-the-7mm-through-2034--delveinsight-302554890.html